Back on Track!

For quitte a while a somewhat dormant condition has been applicable. Covid-19 certainly also played a roll.

But now: happy to announce that we are Back on Track!

In the near future we can tell more about exiting news!

 

EPN biennial forum 2018 in Kampala

In Kampala (Uganda), from 15th-18th May 2018, the Ecumenical Pharmaceutical Network (EPN) biennial forum was held.

The theme of this forum meeting was Medication Safety.

As a member of EPN GIMS was represented by it’s chairman and performed as a speaker, did a poster presentation about the GIMS model and contributed with 3 articles in the EPN electronic magazine Pharmalink.

Valuable contacts were made and follow up activities are investigated.

Link to the articles:

EPN-Poster-GIMS Kampala 2018

GIMS model article EPN forum 2018 v1

EPN article medication safety medication programs

EPN article Sellin-Vanslobbe

 

Tokyo declaration on Patient Safety

On the 14th till 17th of April 2018 a high level meeting took place in Tokyo.

“The Tokyo Declaration on Patient Safety is founded on the policies articulated in World Health Assembly resolution WHA55.18 (2002), which urged Member States to “pay the closest possible attention to the problem of patient safety and establish and strengthen science-based systems, necessary for improving patient safety and the quality of health care”.

“Recognizing that patient safety is one of the most important components of health care delivery which is essential to achieve Universal Health Coverage (UHC), and moving towards UN Sustainable Development Goals (SDGs); and that patient safety systems and practices need to be established in all countries as one of the critical health care standards for achieving UHC on a sustainable basis;” 

GIMS wants to/can contribute through developing and implementing pharmaceutical IT-tools.

Whole text of Tokyo declaration:  Tokyo declaration

GIMS at EPN biennial forum in Kampala

The Ecumenical Pharmaceutical Network (wwe.epnetwork.org) is having it’s biennial forum in Kampala from 15-18 May this year.

The theme will be; ‘ Patient safety, Medication without Harm’.

GIMS foundation will be present and will contribute through a poster presentation and a scientific article about the ‘Gims Model for Screening and Rating of Medication Safety in a Country’.

Medication Safety in donor-sponsored public health programs

As known there are huge sponsored medication access programs by diverse organizations. The Global Fund is one them. In the last decade enormous amounts of medicines (specifically against HIV, TB, Malaria) have been distributed

But has there been attention for the Medication Safety aspect as well??

In the article beneath a first attempt to get more insight.

Medication Safety in donor-sponsored public health programmes

NIA presentation

At a NIA-meeting (Dutch Industry Pharmacists Association) a presentation was given about GIMS foundation.

The theme of much needed improvements in Medication Safety in LMIC’s was picked up well.

Medication Safety in Resource-Limited Settings?

Beneath a fine abstract from a presentation at the Second Global Ministerial Summit on Patient Safety :

Medication Safety in Resource-limited Settings

Priyadarshani Galappatthy, Prof. Dr., Faculty of Medicine, University of Colombo, Professor and Head Department of Pharmacology, Sri Lanka

Abstract: Medication safety is a major concern contributing to patient safety particularly in resource-limited settings (RLS). Absence of reliable estimates of prevalence of adverse drug events, costs involved, causes of medication errors and evidence of effective interventions in RLS is a major limiting factor for ensuring medication safety in RLS.

Although there are nearly five times as many people living in Lower and Middle Income Countries (LMICs), the number of annual adverse drugs events calculated (6 million) is almost equal to the number of adverse drug events occurring in high income countries (5.8 million). Some key problems identified include lack of reliable data, safety culture, reporting systems, poor reporting, poor legibility of hand written prescriptions, absence of electronic support systems, limited number of healthcare professionals to serve the large numbers of patients, lack of clinical pharmacists services, higher prevalence of counterfeit and substandard medicines (up to 20-30% in some LMIC countries), availability of large numbers of generics of the same drug, lack of stringent drug regulatory mechanisms, poor medication literacy and absence of patient support mechanisms.

Possible interventions include identification of the baseline situation on epidemiology and causes of adverse drug events in RLS, the drugs involved in RLS, their severity, amenability of drug events to prevention, implementing routine quality testing of drugs throughout the drug supply chain, implementing successful national drug regulation, increasing the capacity of regulators and providing technological support and expertise for detecting and managing drug related issues.

Expected outcomes would be establishing the baseline on the epidemiology of medication incidents in RLS, implementing systems and practices for medication safety and significant reduction in medication errors (e.g. up to 50%) in the next 5 years. Future direction is towards a multidisciplinary approach with active involvement of all stakeholders in preventing medication incidents. Developing and implementing an individualized action plan for each country for the problems identified based on local data would be the key to ensuring medication safety in RLS.

Keywords: medication safety, medication errors, resource limited settings, lower-middle income countries, prevention

Speaker Information: Priyadarshani Galappatthy is a consultant physician, professor in Pharmacology and Head, Department of Pharmacology, Faculty of Medicine, University of Colombo, Sri Lanka.

For the complete document use link:

Abstracts_and_Speakers_Patient_Safety Ministers Summit 2017